Over the rooftops of Chicago, our team from Department of Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen reflected on inspiring days full of exchange, ideas, and innovation.
From B-cell depleting strategies to the vision of tailored medicine, discussions at ACR2025 showed how fast the field is evolving.
We are proud to contribute to this progress – having conducted the world’s first CAR T-cell therapy in autoimmune diseases and the first T-cell engager therapy in rheumatoid arthritis.
A special highlight: the valuable exchange wi th colleagues from Hannover (MHH), Berlin (Charité), and Kunihiro Yamaoka (Japan), sharing insights that will shape the next generation of immunotherapies.
